A Phase 3 interventional study of Ruxolitinib in Polycythemia Vera, sponsored by Novartis Pharmaceuticals. Completed at 65 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-07-18.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing ruxolitinib in Polycythemia Vera — 5 open to participants now, 8 under way, 1 of them phase 3. ruxolitinib · Polycythemia Vera.
Among the 17 studies testing ruxolitinib in Polycythemia Vera, this one is the 5th largest by enrollment, is one of 2 that started in 2014, is one of 5 in phase 3, and was the 8th registered.
278 studies on the registry are indexed under Polycythemia Vera; 53 are open to participants now.
Browse Polycythemia Vera studies →5 of the 17 studies testing ruxolitinib in Polycythemia Vera are open now, in 3 countries. Recruiting first, the newest first:
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18+
University of Washington · Sites in United States
Ages 18+
University of Birmingham · Sites in United Kingdom
Ages 18+
By country, each count listing its studies:
ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 42 Polycythemia Vera studies recruiting now, 38 (90%) set no upper age limit and 1 (2%) stops at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 8 · Phase 3 5 · Phase 4 1
First in 2007; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 161 is above the median of 52 across 204 interventional studies indexed under Polycythemia Vera.
Median enrollment 110 across the 17 interventional studies. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 17 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
12 studies in Polycythemia Vera by Novartis: none open now, 2 under way, none of them phase 3. Of 7 finished, 3 (43%) have results posted.
Among the 12 studies in Polycythemia Vera by Novartis, this one is one of 2 that started in 2014, is one of 2 in phase 3, and was the 3rd registered.
Novartis’s Polycythemia Vera studies by the year they started, since 2013.
4 of the studies testing ruxolitinib in Polycythemia Vera that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04041050AbbVieA Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | 2026-12-31 |
| NCT05714072Memorial Sloan Kettering Cancer CenterA Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis | 2027-01 |
| NCT04644211Massachusetts General HospitalRuxolitinib in Thrombocythemia and Polycythemia Vera | 2027-07 |
| NCT04282187University of WashingtonDecitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms | 2027-11-11 |
Add all 4 to your calendar (.ics) → With an account.
Among the 17 studies testing ruxolitinib in Polycythemia Vera, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 12 in Polycythemia Vera:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this open-label, single arm, multi-center Expanded Treatment Protocol (ETP) was to provide early access to ruxolitinib and evaluate safety information in patients with polycythemia vera (PV) who were hydroxyurea (HU) resistant or intolerant and who had no other standard treatment option, nor did they qualify for another clinical study for PV
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
•Confirmed diagnosis of PV according to the 2008 World Health Organization criteria, palpable spleen, Resistant to or intolerant of hydroxyurea, performance status of 0, 1 or 2; did not have access to a comparable or satisfactory alternative treatment
Exclusion Criteria:
•Inadequate liver or renal function, Significant bacterial, fungal, parasitic, or viral infection requiring treatment, Active within the past 5 years, except treated cervical intraepithelial neoplasia, basal cell carcinoma of the skin, or squamous cell carcinoma of the skin, with no evidence for recurrence in the past 3 years., Women who were pregnant or nursing.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients will receive ruxolitinib at a starting dose of 10 mg twice daily which could be titrated to most appropriate dose. Dose was not to exceed 25 mg bid nor be less than 5 mg once a day
Drug: Ruxolitinib
supplied as 5 mg, 10 mg and 20 mg tablets to be taken orally
Number of Participants With Adverse Events - All Grades
Summary of adverse events (all grades).
Time frame: Baseline up to approximately 26 months
Change From Baseline in Hematocrit Levels at All Visits
Change in hematocrit levels from Baseline to each visit were measured
Time frame: Up to approximately 26 months
Change From Baseline in Spleen Length
Change in spleen length from Baseline to each visit
Time frame: Up to approximately 26 months
Change From Baseline in Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS)
The MPN-SAF (Appendix 6) was a disease specific questionnaire comprised of 10 items that measures fatigue related to MPN disease and the severity of nine of the most prevalent associated symptoms including: early satiety, abdominal discomfort, inactivity, concentration, night sweats, itching, bone pain, fever and weight loss. There were three recall periods used in this questionnaire, which were 24 hours for fatigue, the past week for symptoms of early satiety, abdominal discomfort, inactivity, concentration, night sweats, itching, bone pain and fever, and the past 6 months for weight loss, Each item was scored on a scale ranging from 0 (no fatigue/absent) to 10 (As bad as you can imagine/worst imaginable). The MPN-SAF TSS was computed as the average of the observed items multiplied by 10 to achieve a 0-to-100 scale. The MPN-SAF TSS thus had a possible score range of 0 to 100.
Time frame: Up to approximately 26 months
| Milestone | All Patients |
|---|---|
| Started | 161 |
| Completed | 141 |
| Not completed | 20 |
| Withdrew: Adverse event | 12 |
| Withdrew: Death | 1 |
| Withdrew: Disease progression | 2 |
| Withdrew: Subject/guardian decision | 2 |
| Withdrew: Withdrawal by subject | 3 |
Summary of adverse events (all grades).
| Participants | All Patients |
|---|---|
| Adverse events | 143 |
| Serious adverse events | 26 |
Change in hematocrit levels from Baseline to each visit were measured
| percentage | Baseline | Post-baseline | Change |
|---|---|---|---|
| Week 4 | 45.26 ± 5.246 | 43.70 ± 5.220 | -1.55 ± 3.652 |
| Week 8 | 45.21 ± 5.136 | 40.73 ± 4.967 | -4.48 ± 5.055 |
| Week 12 | 45.44 ± 5.324 | 39.97 ± 5.419 | -5.47 ± 6.522 |
| Week 16 | 45.64 ± 5.395 | 39.32 ± 5.454 | -6.32 ± 6.928 |
| Week 20 | 45.96 ± 5.353 | 40.47 ± 5.323 | -5.49 ± 6.840 |
| Week 24 | 45.93 ± 5.109 | 40.32 ± 4.960 | -5.62 ± 6.073 |
| Week 36 | 45.30 ± 4.602 | 40.43 ± 4.959 | -4.86 ± 6.184 |
| Week 48 | 45.41 ± 4.714 | 39.82 ± 4.959 | -5.59 ± 6.318 |
| Week 60 | 46.56 ± 5.299 | 40.60 ± 5.105 | 40.60 ± 5.929 |
| Week 72 | 47.66 ± 5.377 | 40.59 ± 4.056 | -7.07 ± 6.388 |
| Week 84 | 48.15 ± 5.758 | 41.93 ± 5.097 | -6.23 ± 6.492 |
| Week 96 | 50.03 ± 4.702 | 40.82 ± 4.496 | -9.21 ± 6.861 |
| EOT | 45.38 ± 5.202 | 39.93 ± 5.730 | -5.45 ± 5.847 |
Change in spleen length from Baseline to each visit
| cm | Baseline | Post-baseline | Change |
|---|---|---|---|
| Week 12 | 23.92 ± 14.618 | 16.83 ± 12.931 | -7.09 ± 12.770 |
| Week 24 | 22.66 ± 14.319 | 16.26 ± 13.896 | -6.40 ± 14.101 |
| Week 36 | 21.87 ± 13.228 | 16.70 ± 14.419 | -5.18 ± 10.929 |
| Week 48 | 22.14 ± 13.994 | 18.76 ± 16.880 | -3.38 ± 14.438 |
| Week 60 | 20.00 ± 13.007 | 17.35 ± 12.357 | -2.65 ± 13.753 |
| Week 72 | 18.41 ± 13.148 | 13.47 ± 11.441 | -4.94 ± 13.840 |
| Week 84 | 19.57 ± 14.233 | 13.36 ± 9.443 | -6.21 ± 12.135 |
| Week 96 | 19.92 ± 14.494 | 12.33 ± 8.026 | -7.58 ± 11.237 |
| End of treatment | 3.03 ± 3.419 | 0.54 ± 1.661 | -2.49 ± 3.025 |
The MPN-SAF (Appendix 6) was a disease specific questionnaire comprised of 10 items that measures fatigue related to MPN disease and the severity of nine of the most prevalent associated symptoms including: early satiety, abdominal discomfort, inactivity, concentration, night sweats, itching, bone pain, fever and weight loss. There were three recall periods used in this questionnaire, which were 24 hours for fatigue, the past week for symptoms of early satiety, abdominal discomfort, inactivity, concentration, night sweats, itching, bone pain and fever, and the past 6 months for weight loss, Each item was scored on a scale ranging from 0 (no fatigue/absent) to 10 (As bad as you can imagine/worst imaginable). The MPN-SAF TSS was computed as the average of the observed items multiplied by 10 to achieve a 0-to-100 scale. The MPN-SAF TSS thus had a possible score range of 0 to 100.
| scores | Baseline | Post-baseline | Change |
|---|---|---|---|
| Week 12 | 23.92 ± 14.618 | 16.83 ± 12.931 | -7.09 ± 12.770 |
| Week 24 | 22.66 ± 14.319 | 16.26 ± 13.896 | -6.40 ± 14.101 |
| Week 36 | 21.87 ± 13.228 | 16.70 ± 14.419 | -5.18 ± 10.929 |
| Week 48 | 22.14 ± 13.994 | 18.76 ± 16.880 | -3.38 ± 14.438 |
| Week 60 | 20.00 ± 13.007 | 17.35 ± 12.357 | -2.65 ± 13.753 |
| Week 72 | 18.41 ± 13.148 | 13.47 ± 11.441 | -4.94 ± 13.840 |
| Week 84 | 19.57 ± 14.233 | 13.36 ± 9.443 | -6.21 ± 12.135 |
| Week 96 | 19.92 ± 14.494 | 12.33 ± 8.026 | -7.58 ± 11.237 |
| End of treatment | 22.86 ± 14.225 | 18.12 ± 15.130 | -4.74 ± 13.954 |
Collected over Adverse Events (AEs) were collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 26 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| All Patients | 1/161 (0.6%) | 26/161 (16.1%) | 107/161 (66.5%) |
| Event | All Patients |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 2/161 |
| PneumoniaInfections and infestations | 2/161 |
| Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/161 |
| Bundle branch block bilateralCardiac disorders | 1/161 |
| PericarditisCardiac disorders | 1/161 |
| Ventricular extrasystolesCardiac disorders | 1/161 |
| CataractEye disorders | 1/161 |
| AscitesGastrointestinal disorders | 1/161 |
| DiarrhoeaGastrointestinal disorders | 1/161 |
| Retroperitoneal haematomaGastrointestinal disorders | 1/161 |
| Event | All Patients |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 35/161 |
| HeadacheNervous system disorders | 27/161 |
| DiarrhoeaGastrointestinal disorders | 15/161 |
| ConstipationGastrointestinal disorders | 14/161 |
| FatigueGeneral disorders | 14/161 |
| Weight increasedInvestigations | 13/161 |
| PruritusSkin and subcutaneous tissue disorders | 13/161 |
| AstheniaGeneral disorders | 12/161 |
| DizzinessNervous system disorders | 12/161 |
| ThrombocytosisBlood and lymphatic system disorders | 11/161 |
| Age, Customized(participants) | All Patients |
|---|---|
| <= 60 | 52 |
| >60 | 109 |
| Sex: Female, Male(Participants) | All Patients |
|---|---|
| Female | 65 |
| Male | 96 |
| Race/Ethnicity, Customized(participants) | All Patients |
|---|---|
| Caucasian | 128 |
| Asian | 3 |
| Other | 30 |
| Number of participants resistant or intolerant to hydroxyurea (HU)(participants) | All Patients |
|---|---|
| Resistant to hydroxyurea | 60 |
| Intolerant to hydroxyurea | 101 |
| Number of participants' frequency of phlebotomy in 52 weeks prior to screening(participants) | All Patients |
|---|---|
| 1 phlebotomy | 21 |
| 2 phlebotomies | 19 |
| >=3 phlebotomies | 74 |
| Missing | 47 |
| Number of participants' use of prior antineoplastic therapy(participants) | All Patients |
|---|---|
| Prior Hydroxyurea use | 160 |
| Prior other anti-neoplastic medications use | 59 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2014 to primary completion in Dec 2017, 37 months.
Results were first posted in Apr 2019, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ruxolitinib